Connection

Co-Authors

This is a "connection" page, showing publications co-authored by SUE-HWA LIN and YU-CHEN LEE.
Connection Strength

3.098
  1. Targeting constitutively activated ?1 integrins inhibits prostate cancer metastasis. Mol Cancer Res. 2013 Apr; 11(4):405-17.
    View in: PubMed
    Score: 0.440
  2. Plasma membrane isolation using immobilized concanavalin A magnetic beads. Methods Mol Biol. 2012; 909:29-41.
    View in: PubMed
    Score: 0.409
  3. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res. 2011 Aug 01; 71(15):5194-203.
    View in: PubMed
    Score: 0.394
  4. Androgen depletion up-regulates cadherin-11 expression in prostate cancer. J Pathol. 2010 May; 221(1):68-76.
    View in: PubMed
    Score: 0.365
  5. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene. 2010 Jun 03; 29(22):3196-207.
    View in: PubMed
    Score: 0.361
  6. Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment. Mol Cell Proteomics. 2015 Mar; 14(3):471-83.
    View in: PubMed
    Score: 0.126
  7. Angiomotin is a novel component of cadherin-11/?-catenin/p120 complex and is critical for cadherin-11-mediated cell migration. FASEB J. 2015 Mar; 29(3):1080-91.
    View in: PubMed
    Score: 0.125
  8. Cadherin-11 in renal cell carcinoma bone metastasis. PLoS One. 2014; 9(2):e89880.
    View in: PubMed
    Score: 0.119
  9. Aberrant expression of katanin p60 in prostate cancer bone metastasis. Prostate. 2012 Feb; 72(3):291-300.
    View in: PubMed
    Score: 0.099
  10. Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res. 2010 Jun 01; 70(11):4580-9.
    View in: PubMed
    Score: 0.091
  11. One-step isolation of plasma membrane proteins using magnetic beads with immobilized concanavalin A. Protein Expr Purif. 2008 Dec; 62(2):223-9.
    View in: PubMed
    Score: 0.081
  12. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res. 2008 Aug; 6(8):1259-67.
    View in: PubMed
    Score: 0.081
  13. Expression of the extracellular domain of OB-cadherin as an Fc fusion protein using bicistronic retroviral expression vector. Protein Expr Purif. 2008 Oct; 61(2):220-6.
    View in: PubMed
    Score: 0.080
  14. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res. 2008 Jun 15; 14(12):3729-36.
    View in: PubMed
    Score: 0.080
  15. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene. 2008 Sep 04; 27(39):5195-203.
    View in: PubMed
    Score: 0.080
  16. Expression of recombinant MDA-BF-1 with a kinase recognition site and a 7-histidine tag for receptor binding and purification. Protein Expr Purif. 2005 Nov; 44(1):58-64.
    View in: PubMed
    Score: 0.067
  17. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. Clin Cancer Res. 2014 Dec 15; 20(24):6570-81.
    View in: PubMed
    Score: 0.031
  18. RSK promotes G2/M transition through activating phosphorylation of Cdc25A and Cdc25B. Oncogene. 2014 May 01; 33(18):2385-94.
    View in: PubMed
    Score: 0.028
  19. The CHMP4b- and Src-docking sites in the Bro1 domain are autoinhibited in the native state of Alix. Biochem J. 2009 Mar 01; 418(2):277-84.
    View in: PubMed
    Score: 0.021
  20. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. Br J Cancer. 2008 Nov 04; 99(9):1426-32.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.